Ticker LaunchDirect listing · FBLG
FibroBiologics, Inc.
Formerly FibroBiologics Inc.
FibroBiologics, Inc. (FBLG) went public through a direct listing on Nasdaq Global Market on Jan 31, 2024. Norton Rose Fulbright advised the company.
FibroBiologics, Inc. is a clinical-stage cell therapy company developing fibroblast-based therapies for chronic diseases, including degenerative disc disease, multiple sclerosis, wound healing and certain cancers. It was formed in April 2021 as a Texas limited liability company.
- Status
- Direct listing
- Ticker
- FBLG
- Exchange
- Nasdaq Global Market
- Listed
- Jan 31, 2024
- First filed
- Nov 7, 2023
- Company counsel
- Norton Rose Fulbright
- Sector
- Biotech & pharma
- Country / state
- TX
More on this listing for subscribers
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Nov 7, 2023
- Latest amendment Jan 24, 2024
- Final prospectus (424B4) Jan 31, 2024
- All filings on EDGAR CIK 1958777